
Key specifications and handling guidance.
Everything you need to know before starting.
Ostarine, also known as MK-2866, MK2866, Enobosarm, and GTx-024, is an investigational nonsteroidal selective androgen receptor modulator (SARM) that has been extensively studied for its interaction with androgen receptors.
Unlike many experimental compounds that remain limited primarily to preclinical research, Enobosarm has progressed through multiple stages of human clinical investigation in addition to laboratory and animal studies.
This Ostarine formulation is produced with a focus on consistency, purity and analytical verification for research applications.
Ostarine is the commonly used name for Enobosarm, an investigational selective androgen receptor modulator.
It is also widely identified by the developmental names MK-2866 and GTx-024.
SARMs are compounds designed to interact selectively with androgen receptors. Research into Ostarine has focused heavily on androgen-receptor signaling and its effects in tissues such as skeletal muscle and bone.
Because several different names appear throughout scientific literature and online research, Ostarine, MK-2866, MK2866, GTx-024 and Enobosarm generally refer to the same investigational compound.
Ostarine acts through the androgen receptor, a nuclear receptor involved in regulating numerous androgen-responsive biological processes.
Researchers developed selective androgen receptor modulators to investigate whether androgen-receptor activity could be targeted more selectively across different tissues than with conventional steroidal androgens.
Ostarine has therefore been investigated in models involving skeletal muscle, body composition, physical function, bone biology and other androgen-responsive pathways.
Ostarine is notable among investigational SARMs because its scientific history includes both preclinical research and human clinical trials.
Research involving Enobosarm has examined areas including:
Enobosarm has been evaluated in randomized controlled human studies and progressed into Phase 3 clinical development for the investigation of muscle wasting in patients with cancer.
The existence of clinical research does not mean that Ostarine is an approved medication, nutritional supplement or bodybuilding product.
Yes.
Ostarine/MK-2866 is classified as a selective androgen receptor modulator, commonly abbreviated as SARM.
This differentiates Ostarine from compounds that are sometimes marketed alongside SARMs despite working through unrelated biological pathways.
Ostarine’s primary research mechanism centers on interaction with the androgen receptor.
Compound: Enobosarm
Common names: Ostarine, MK-2866, MK2866, GTx-024
Classification: Selective androgen receptor modulator (SARM)
Form: Liquid
Concentration: 20 mg/mL
Bottle volume: 30 mL
Purity: ≥99%
Carrier: MCT oil
Quality control: Batch-tested with analytical verification
Storage: Store in a cool, dark and dry environment.
Accurate compound identity, concentration, purity and storage conditions are important considerations for controlled research applications.
Research compounds require consistency to support reproducible experimental work.
LRG Labs Ostarine is produced with an emphasis on compound identity, concentration and analytical consistency. Each batch undergoes quality-control procedures intended to verify the material’s specifications.
Where available, batch-specific analytical documentation can provide researchers with additional information about compound identity and purity.
Ostarine is a nonsteroidal selective androgen receptor modulator, whereas traditional anabolic-androgenic steroids are steroidal compounds.
Both may interact with androgen-related biological pathways, but their chemical structures and pharmacological properties are different.
One of the central areas of SARM research has been investigating whether selective modulation of androgen receptors can create different tissue-specific biological responses compared with traditional steroidal androgens.
The term “selective” should not be interpreted as meaning that a compound has been established as safe for unsupervised human use.
The scientific literature surrounding Ostarine is more extensive than laboratory and animal research alone.
Enobosarm has undergone human clinical investigation, including randomized, double-blind, placebo-controlled research evaluating body composition and physical-function endpoints.
Clinical programs have also investigated Enobosarm in patients experiencing cancer-associated muscle wasting.
These studies are important for understanding the scientific development of MK-2866 but should not be interpreted as establishing Ostarine as an approved medication or supplement.
Yes.
Ostarine, MK-2866, MK2866, GTx-024, and Enobosarm are names commonly associated with the same investigational selective androgen receptor modulator.
Enobosarm is the name frequently used in clinical research, while Ostarine and MK-2866 are particularly common in general SARM discussions.
Understanding these naming variations is useful when searching scientific databases because different publications may use different terminology.
Ostarine is an investigational nonsteroidal selective androgen receptor modulator commonly known as MK-2866 or Enobosarm.
Yes. MK-2866 is one of the developmental names commonly associated with Ostarine/Enobosarm.
Yes. MK2866 and MK-2866 are simply different ways of formatting the same research designation.
Yes. Enobosarm is another commonly used name for the compound widely known as Ostarine.
Yes. Ostarine is classified as a selective androgen receptor modulator.
Ostarine interacts with the androgen receptor and has been investigated for tissue-selective androgen-receptor activity.
Yes. Enobosarm has undergone multiple human clinical studies, including randomized controlled research and later-stage clinical development.
Health Canada identifies Ostarine (MK-2866) as a SARM and states that SARMs have not been authorized in Canada for medical use.
“Ostarine Canada,” “MK-2866 Canada” and “MK2866 Canada” are common search terms used by people researching Enobosarm, scientific studies, Canadian regulatory information and the compound’s research background.
Ostarine remains an investigational compound and should not be represented as an approved dietary supplement or approved medical treatment.
Scientific findings involving Ostarine should be interpreted according to the specific study population, experimental design, endpoints and limitations of the available research.
More Ostarine information:
Ostarine, also known as MK-2866 or Enobosarm, has been the subject of extensive preclinical and experimental research. Studies have explored its selective interaction with androgen receptors in muscle and bone tissue models.
Research has investigated Ostarine for its potential role in muscle maintenance, recovery signaling, and age-related tissue studies, all conducted in controlled laboratory or animal environments.
This liquid Ostarine is produced with a focus on consistency and analytical accuracy. Each batch undergoes quality control testing to confirm purity and concentration for research reliability.
Ostarine is offered strictly as a research compound. It is not intended for human consumption or medical use. All referenced effects are based solely on experimental findings.
Complete your stack with complementary picks.